Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Adv Healthc Mater. 2019 May 8;8(11):e1801553. doi: 10.1002/adhm.201801553

Figure 5.

Figure 5.

Bioactivity of released protein therapeutics from 3D printed structure. (a) Schematic of invasion assay (b)Actin and nuclei staining of migrate HUVECs across transwell. Addition of growth factor to PEGDTT/nSi influences cell migration. SEM images of deposited extracellular matrix (outlined in white) due to cell migration. (c) Quantification of invading cells (n=5, *p<0.05, one-way ANOVA with Tukey post-hoc testing). (d) Live/dead image showing high viability (~85%) of encapsulated cells within 3D printed structure. (e) 3D bioprinted scaffolds loaded with HUVECs stained via cell tracker. (f) VEGF loaded PEGDTT/nSi bioink direct migration of HUVECs encapsulated in surrounding GelMA hydrogels (day 7). Cells migrated towards the PEGDTT/nSi due to the bioavailabilty of VEGF.